Twitter, Gap and 3 Other Stocks Are Making Headlines Today

Petroleo Brasileiro SA Continues to Rise After Debt Offering

Petroleo Brasileiro SA Petrobras (ADR) (NYSE:PBR) has witnessed its gains of Thursday extend into Friday, following the company raising approximately $7.5 billion in a reopened debt offering. Proceeds from the offering will be used to refinance existing debt which have shorter durations and for operating purposes. Petroleo Brasileiro also revealed this morning that it had raised $3 billion through the reopening of an overseas bond issuance to finance a new buyback program of certain outstanding notes. Petroleo’s shares have gained over 4% this morning.

Among the funds tracked by Insider Monkey, 23 firms were shareholders of Petroleo Brasileiro SA Petrobras (ADR) (NYSE:PBR) at the end of the first quarter. Ken Fisher’s Fisher Asset Management owned more than 10.5 million shares of the company at that time.

Twitter in Talks For Digital Content Streaming Rights

Twitter Inc (NYSE:TWTR)’s stock has climbed more than 2% in the green on Friday following a report from Re/code which claimed that the social media giant is in talks with the NBA, Major League Soccer and cable network Turner to acquire rights to stream live sports and other events. The source added that the content which Twitter wants to stream could include live streams of matches or pre- and post-game analysis and interviews. Twitter’s interest in Turner is mainly due to the cable company already enjoying the rights to several major sports leagues including the NBA, MLB, and the NCAA Men’s Basketball Tournament. A total of 27 funds in our database were long Twitter Inc (NYSE:TWTR) as of the end of March, down from 30 hedge funds a quarter earlier.

FDA Puts Hold on Juno Therapeutics’ Cancer Drug Trial

Juno Therapeutics Inc (NASDAQ:JUNO) is not enjoying the same green day as the other stocks covered in this article, as its shares have nosedived by more than 29% after the company announced that it had received a notice from the U.S. Food and Drug Administration (FDA) that a ‘clinical hold’ has been put on its Phase 2 trial of JCAR15, a drug to treat acute lymphoblastic leukemia. The hold was enforced after two patients who were part of the trial died last week. At the end of the first quarter, 14 hedge funds in our database were long Juno Therapeutics Inc (NASDAQ:JUNO), down from 17 hedge funds a quarter earlier.

Disclosure: None